Athersys, Inc. (NASDAQ:ATHX)

CAPS Rating: 1 out of 5

ATHX News and Commentary

Caps

How do you think ATHX will perform against the market?

Add Stock to CAPS Watchlist

All Players

83 Outperform
18 Underperform
 

All-Star Players

5 Outperform
12 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top ATHX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Dublin43016 (< 20)
Submitted February 22, 2014

1. Recent regulatory changes to accelerate regenerative medicine use in Japan, will allow faster development of their products. CEO has already made several trips so as to get his ducks in a row.2.Second quarter results on phase II study on… More

zzlangerhans (99.72)
Submitted January 11, 2016

I just wasted close to an hour trying to translate pages of handwaving from the last Athersys conference call into actionable information. My takeaway: I'm supposed to ignore all the negative developments over the last few years with MultiStem… More

ATHX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ATHX.

Recs

0
Member Avatar jw2net (< 20) Submitted: 2/19/2016 11:33:47 AM : Outperform Start Price: $1.64 ATHX Score: -15.75

athx

Recs

0
Member Avatar zzlangerhans (99.72) Submitted: 2/3/2016 3:56:25 PM : Underperform Start Price: $1.28 ATHX Score: -16.69

Nothing new from my last red thumb except an inexplicable price rebound despite a crashing sector, so I'll repost my last pitch.

I just wasted close to an hour trying to translate pages of handwaving from the last Athersys conference call into actionable information. My takeaway: I'm supposed to ignore all the negative developments over the last few years with MultiStem because cytokines. Add this to the company's recent Enjo Kosai activities with various small Japanese pharmas and we have a market cap of 104M, cash of about 40M (inclusive of Healios upfront payment), and a probable inert stem cell soup therapy. Athersys share price is holding up while former darlings StemCells, Caladrius, and Pluristem are going down the toilet but don't expect that to last long as spec biotech remains volatile and new positive catalysts fail to appear during the year.

Recs

0
Member Avatar LifeScientist (22.25) Submitted: 1/11/2016 3:03:33 PM : Underperform Start Price: $1.23 ATHX Score: -25.17

overstated reporting in annual

Leaderboard

Find the members with the highest scoring picks in ATHX.

No players have picked ATHX yet. Tell us why you think ATHX will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackwbbsecuriti < 20 9/13/2010 Outperform NS $3.00 -32.67% +136.82% -169.48 0 Comment

Featured Broker Partners